Biotech entity
Central Drugs Standard Control Organisation (CDSCO) is most often covered alongside Delhi High Court, which appears in 1 of these 2 stories. Source depth averages 2 original sources per story, versus 4 across the same-window beat baseline. The 132-day window averages about 0.1 stories each week.
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Central Drugs Standard Control Organisation (CDSCO) is most often covered alongside Delhi High Court, which appears in 1 of these 2 stories. Source depth averages 2 original sources per story, versus 4 across the same-window beat baseline. The 132-day window averages about 0.1 stories each week. At 6, the average consequence score sits below the same-window beat average of 6.4. fda-approval accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. This profile follows 2 Biotech stories mentioning Central Drugs Standard Control Organisation (CDSCO) across the period from March 18, 2026 to July 27, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 289 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Central Drugs Standard Control Organisation (CDSCO). Shared-story counts are live from our verified record — not editorial picks.
Contempt Petition Filed
Petitioners allege CDSCO failed to act on the court's previous directions.
Contempt Notice Issued
Justice Sachin Datta seeks a formal response from CDSCO regarding the delay.
Original Court Order
Delhi HC directs CDSCO to examine safety and regulatory concerns of diabetes drugs used for weight management.
Faster licensing for high-risk medical devices in India could streamline drug-delivery and diagnostic tool availability for biotech firms, speeding up clinical trial timelines and reinforcing the nation's pharma hub status.
The Delhi High Court has initiated contempt proceedings against India's top drug regulator, the CDSCO, for failing to examine safety concerns regarding the off-label use of diabetes medications for weight loss. This judicial escalation highlights growing concerns over the unregulated boom of GLP-1 agonists in the Indian market.
Central Drugs Standard Control Organisation (CDSCO) is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
